Michael Vincent Meluzio

CIK: 0002138368

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)4 (66.7%)

Position reduction

Option Exercises (M)1 (16.7%)

Derivative conversions

Awards (A)1 (16.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

CUE

Cue Biopharma, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

CUE
Cue Biopharma, Inc.
Oct 12, 2026
Sale(S)
Direct
1.1K shares at avg. $28.05$32K
CUE
Cue Biopharma, Inc.
Aug 13, 2026
Exercise(M)
Direct
13.6K shares-
CUE
Cue Biopharma, Inc.
Aug 13, 2026
Sale(S)
Direct
1.5K shares at avg. $29.37$45K
CUE
Cue Biopharma, Inc.
Aug 13, 2026
Sale(S)
Direct
4.1K shares at avg. $30.35$125K
CUE
Cue Biopharma, Inc.
Aug 13, 2026
Sale(S)
Direct
3 shares at avg. $31.13$93.39
CUE
Cue Biopharma, Inc.
Jul 9, 2026
Award(A)
Direct
40.9K shares-

		Type	Shares	Price		Ownership
Oct 12, 2026	CUE Cue Biopharma, Inc.	Sale(S)	1,144	$28.05	$32,089	Direct
Aug 13, 2026	CUE Cue Biopharma, Inc.	Exercise(M)	13,647	-	$0	Direct
Aug 13, 2026	CUE Cue Biopharma, Inc.	Sale(S)	1,519	$29.37	$44,613	Direct
Aug 13, 2026	CUE Cue Biopharma, Inc.	Sale(S)	4,106	$30.35	$124,617	Direct
Aug 13, 2026	CUE Cue Biopharma, Inc.	Sale(S)	3	$31.13	$93	Direct
Jul 9, 2026	CUE Cue Biopharma, Inc.	Award(A)	40,942	-	$0	Direct

1-6 of 6 transactions

About Meluzio Michael Vincent

Meluzio Michael Vincent (SEC CIK 0002138368) files insider reports with the SEC as VP, Prin. Accounting Officer of Cue Biopharma, Inc. (CUE).

Signal8 holds 4 ownership filings by Meluzio Michael Vincent (1 Form 3, 3 Form 4), filed between Jun 11, 2026 and Oct 14, 2026. Those filings report 6 transactions, from Jul 9, 2026 to Oct 12, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Meluzio Michael Vincent's filings is in SOMERVILLE, MA.

Recent filings by Meluzio Michael Vincent

Oct 12, 2026: Open-market sale of CUE shares (Form 4, code S).
Aug 13, 2026: Option exercise of CUE shares (Form 4, code M).
Aug 13, 2026: Open-market sales of CUE shares (3 lines, Form 4, code S).
Jul 9, 2026: Grant or award of CUE shares (Form 4, code A).

Other insiders filing for Cue Biopharma, Inc. (CUE)

Ray Sumita, Chief Legal Compliance Officer
Lin Shao-Lee, Chief Executive Officer
Sarraf Pasha, Director
Garzone Pamela, Director
Ahlers James M, Chief Financial Officer
Borie Dominique Christian, Chief Medical Officer

How to read Form 4 transaction codes